Skip to content
Press Releases

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte To Present At 2014 Leerink Global Healthcare Conference
SOUTH SAN FRANCISCO , Feb. 5, 2014 /PRNewswire/ --  Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , president and chief executive officer, will present at the 2014 Leerink Global Healthcare Conference on Wednesday, February 12, 2014 at 11:30 a.m. ET in New York .
View HTML
Toggle Summary Veracyte Announces Cigna Coverage for the Afirma® Gene Expression Classifier
SOUTH SAN FRANCISCO, Calif. , Dec. 16, 2013 /PRNewswire/ --  Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced that Cigna, one of the nation's leading providers of health insurance, has issued a positive coverage policy for
View HTML
Toggle Summary Veracyte, Inc. Announces Third Quarter 2013 Financial Results
-- 3Q Revenue Reached $5.6 Million, Increasing 74% Compared to Prior Year ---- Coverage and Reimbursement Continue to Expand for Afirma® Gene Expression Classifier (GEC) ---- Company Successfully Completed Initial Public Offering on November 4 ---- Conference Call Today at 5 p.m. ET --
View HTML
Toggle Summary Veracyte Presents Data Suggesting Ability of Its Afirma® Gene Expression Classifier To Detect Medullary Thyroid Cancer Among Indeterminate Thyroid Nodule Biopsies
SOUTH SAN FRANCISCO, Calif. , Nov. 13, 2013 /PRNewswire/ --  Veracyte, Inc. (Nasdaq: VCYT) today announced that it presented new data suggesting the ability of its Afirma Gene Expression Classifier (GEC) to accurately identify medullary thyroid cancer (MTC) among thyroid nodule fine needle
View HTML
Toggle Summary Veracyte, Inc. to Announce Third Quarter 2013 Financial Results and Host Conference Call on Monday, November 25, 2013
SOUTH SAN FRANCISCO, Calif. , Nov. 11, 2013 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) announced today that its third quarter 2013 financial results will be released after close of market on Monday, November 25 , 2013.  Following the release, Veracyte will host a live conference call and webcast
View HTML
Toggle Summary Veracyte, Inc. Announces Closing of Initial Public Offering
SOUTH SAN FRANCISCO, Calif. , Nov. 4, 2013 /PRNewswire/ --  Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its initial public offering of 5,000,000 shares of its common stock resulting in net proceeds of approximately $58.0 million after deducting underwriting discounts and
View HTML
Toggle Summary Veracyte, Inc. Announces Pricing of Initial Public Offering
SOUTH SAN FRANCISCO, Calif. - October 30, 2013 - Veracyte, Inc. announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $13.00 per share.   All of the shares of common stock are being offered by Veracyte.
View HTML
Toggle Summary Long-Term, Multicenter Outcome Study Confirms Clinical Validity and Clinical Utility of Veracyte's Afirma Gene Expression Classifier
South San Francisco, Calif. --- October 23, 2013 --- Data from a new long-term, multicenter study confirm the accuracy of the Afirma Gene Expression Classifier (GEC) in identifying benign thyroid nodule fine needle aspiration (FNA) biopsies among those initially deemed indeterminate, or
View HTML
Toggle Summary Veracyte Presents Preliminary Data Suggesting Potential for an RNA-Based Gene Expression Test to Detect the BRAF V600E Mutation in Thyroid Nodule Biopsy Samples
Findings Presented at 83rd Annual Meeting of the American Thyroid Association
View HTML
Toggle Summary Veracyte, Inc. Files Registration Statement for Initial Public Offering
South San Francisco, Calif. – September 20, 2013 - Veracyte, Inc. today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed initial public offering of its common stock. All of the shares to be sold in the proposed
View HTML